Walter M. Stadler, MD
Fred C. Buffett Professor of Medicine
Director, Genitourinary Program
Associate Dean for Clinical Research
University of Chicago
1 credit hour
THIS ACTIVITY WAS ORIGINALLY PRESENTED AS A LIVE GRAND ROUNDS SERIES BEGINNING JULY 25, 2011. IF YOU RECEIVED CREDIT FOR PARTICIPATING IN ONE OF THE LIVE ACTIVITY, YOU ARE NOT ELIGIBLE TO RECEIVE CREDIT FOR THIS ONLINE ACTIVITY.
Renal cell carcinoma (RCC) is associated with significant morbidity, mortality, and economic burden. This disease accounts for 90% of all kidney cancers (which are the seventh and ninth most common cancers in men and women, respectively), and is associated with a 5-year survival of 10% in the case of metastasis. The standard of care for advanced RCC has changed significantly with the development of novel targeting agents. Within the past 4 years, 6 agents have been added to the armamentarium for advanced RCC, leading to revised recommendations, which were based on what little clinical data were available.
RCC is a challenging condition to treat, as many patients demonstrate relative resistance to radiation and chemotherapy, and postsurgical recurrence is a frequent phenomenon. The challenges associated with advanced RCC treatment are compounded by the unrelenting flow of clinical findings and research being published on an annual basis. It is imperative that oncologists be aware of best practices associated with the treatment of advanced RCC in order to achieve optimal outcomes in individuals with advanced RCC. The goal of continuing education activities for oncologists must be to expand their knowledge and competency in best practices related to advanced RCC.
. Target Audience
This activity is designed for oncologists, oncology nurses, and other medical professionals interested and involved in the treatment of patients with RCC.
Upon completion of this educational activity, the participant should be able to:
Review the key evidence for treatment practices for advanced and metastatic RCC.
Discuss optimal treatment strategies for advanced RCC utilizing approved systematic therapies and late-breaking clinical data.
Outline strategies for appropriate discontinuation of therapy based on best available evidence.
Summarize how approved agents and therapeutic combinations for advanced RCC may be associated with improved outcomes.
Describe the emerging landscape of investigational agents for advanced and metastatic RCC.
Outline tumor staging and site-specific prognostic indicators for RCC per guidelines and standards.
The University of Cincinnati is committed to offering CME programs that promote improvements or quality in healthcare. It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our sponsored educational programs. Faculty are required to disclose any real or apparent conflict(s) of interest related to the content of this CME activity. Disclosure of a relationship is not intended to suggest or condone bias, but is made to provide learners with information that may be of importance in their evaluation of the materials.
Dr. Stadler: Consultant: Novartis, Pfizer/Wyeth, Roche/Genentech, Takeda, Caremark/CVS, Aveo, NCI/SAIC-Frederick; Speakers Bureau: Pfizer;
Grant/Research Support: Active Biotech, Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Novartis, Genentech (Roche), GlaxoSmithKline, Medarex, Medivation, Solvay (Abbott), Pfizer, ImClone (Lilly), Amgen, Takeda (Millenium), NIH, CALGB; Stockholder: Abbott (Spouse).
Planning Committee Disclosure Statement
Planning committee members have no financial relationships to disclose.
Product Disclosure Information
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult the full prescribing information before using any product mentioned in the newsletter. When using drugs in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosage and uses of the drugs. Neither the publisher nor the sponsor promotes the use of any agent outside of approved labeling. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This activity has been planned and implemented in accordance with the Essentials Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of University of Cincinnati, College of Medicine Office of Continuing Medical Education and Medical Communications Media, Inc. University of Cincinnati, College of Medicine Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
University of Cincinnati designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
University of Cincinnati
Continuing Medical Education
College of Medicine
3225 Eden Avenue, G24 Wherry Hall
Cincinnati, OH 45267
Commercial Support Statements
This activity is supported by an educational grant from Genentech BioOncology.
Commercial Support Guidelines
If any activity is supported by funds from a commercial source such as a pharmaceutical company or an equipment manufacturer it is very important that the Standards for Commercial Support are followed. In general, commercial entities may support CME activities through unrestricted grants. A commercial supporter may not exert undue influence in the form of determining content, choosing speakers, directly paying honoraria to faculty or paying registration fees of attendees. An acknowledgement of any educational support from a commercial company must appear in program brochures, syllabi, and other program materials.
Minimum System Requirements:
• Pentium III, 600 MHz or Equivalent Processor
• 512 MB of RAM
• Windows XP, Vista, or 7
• Mac OS X
• 800x600 Monitor Resolution
• 16-bit Color
• 16 bit Sound Card with Speakers
Please turn off all pop-up blockers to assure access to the educational activity.
Click on the "Start program" icon at the bottom of this page. If you are not already registered as a user of this website, this will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. The activity will take approximately 30 minutes to complete.
After the activity has finished, click on the "Post-test" button.
Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen.
© 2011, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, University of Cincinnati Office of CME, or Genentech BioOncology. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.